| INTRODUCTION
Apoptosis is a complex and highly orchestrated cellular process, and disruption of the balance between induction and inhibition of apoptosis plays key roles in progression of a number of diseases. A well-studied example of this is the identification and study of apoptosis inhibition as a key hallmark of cancer. [1] The Bcl-2 family is a related group of regulatory proteins that play critical roles in cellular apoptosis, either by inducing (pro-apoptotic) or inhibiting (antiapoptotic) apoptosis. [2] Bcl-2 itself, the prototypical member of this family, is an important anti-apoptotic protein that has been the target of a number of drug discovery and development efforts over recent years. [3] Inhibition of anti-apoptotic family members such as Bcl-2 itself has become an attractive therapeutic strategy as Bcl-2 inhibition should lead to a selective (non-genotoxic) pro-apoptotic cascade from which cancer cells cannot easily recover. A number of small-molecule Bcl-2 inhibitors have been developed that have progressed to clinical development; prominent among these are the BH3-mimetic structural analogues ABT-737 and ABT-263 (Navitoclax, Figure 1 ), which also inhibit Bcl-2 family members Bcl-X L and Bcl-w and are currently under investigation in a number of combination studies. [4] Obatoclax mesylate ( Figure 1 ) is a pan-Bcl-2 inhibitor under clinical investigation in the leukemia and lymphoma field. [5] Venetoclax ( Figure 1 , formerly known as ABT-199), a selective and orally bioavailable Bcl-2 inhibitor structurally related to ABT-737/263, is progressing with FDA "Breakthrough Designation" into Phase III development in acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) following encouraging Phase II data in these settings. [6] Our own previous investigations into the discovery of new indole-based Bcl-2-inhibitory pro-apoptotic agents [7] have included the identification of antitumour indolyl-oxadiazoles, [8] indolyl-isoxazoles, [9] and indolyl-triazolamines. [10] In this paper, we report the computational design, virtual screening, analogue synthesis, and in
vitro evaluation of new Bcl-2 inhibitory agents based on an indolylamino-oxadiazole scaffold.
| Virtual screening and initial in vitro biological evaluation
Our virtual screening began with the construction of a 3D pharmacophore model for Bcl-2 inhibitor design within the Molecular Operating Environment from Chemical Computing Group. [11] A database of 12 reported active compounds was created (1YSW (12), 1YSI (12), 2O2F, [12] ABT-737, [13] TW-37, [14] TM-1206, [15] acylpyrogallol, [15] YC137, [16] BHI-1, [17] BHI-2, [17] HA 14-1, [18] and NSC365400 [19] ). Three of the twelve compounds were derived directly from their 3D NMR structure in complex with Bcl-2 protein (PDB code: 1YSW, 1SYI and 2O2F). These latter structures were used to create the 3D model, by refining the existing alignment of their crystallized conformation followed by flexible alignment of another active compound [14] (TW-37) with the fixed aligned structures. Taking into account the four main interactions previously reported [14] that are needed for the stabilization of the complex between pro-apoptotic Bim and anti-apoptotic Bcl-2, a seven feature 3D pharmacophore model was built (Figure 2 ). In an effort to discover novel inhibitors of anti-apoptotic Bcl-2, a druglike subset database from the ZINC database (http://zinc.docking.org/subset1/3/index.html) was downloaded and filtered using the ADME filter within MOE. As druglike molecules, most molecules had an acceptable ADME profile, so the reduction in the size of the database was neglected. The starting number of virtual molecules was 530,000 compounds. Conformational import with strain limit of 4 kcal/mol of all molecules was run to take flexibility into account. The database was tested against the built 3D pharmacophore model (F1 and F4 as essential features, at least one of F6 and F7, at least one of F3 and F5 and enabling partial match to a minimum of five features), which reduced the number of molecules to 15,880. The NMR structure of Bcl-2 co-crystallized with a ligand related to the lead Bcl-2 inhibitory agent ABT-737 (PDB code: 1YSW) was retrieved from the Protein Data Bank (PDB) for docking of successful molecules into the active site using FlexX. [20] After ranking of the docked molecules and visual inspection of the binding modes of the highest scoring molecules, 259 molecules were selected. Of these, 15 compounds were chosen for synthesis and testing as Bcl-2 inhibitors based on considerations of interaction score and binding interactions. All 15 compounds (shown in Figure 3 ) were tested for their inhibitory activity in vitro on two human cancer cell lines (cervical HeLa and breast MDA-MB-231) using the colorimetric MTT cell proliferation assay (72 hr) to assess viability (Table 1) . These two cancer cell lines are well established in our laboratory for the initial screening for growth inhibitory activity of newly synthesized compounds. The MDA-MB-231 breast cancer cell line is known to express Bcl-2 and previous studies have shown downregulation of Bcl-2 in these cells by Western blot analysis following inhibitor treatment. [21] Stable expression of Bcl-2 in the HeLa cell line is also well known. [22] The most active compounds, based on viability assays, from this initial series (compounds 1, 2, 6 and 8) were chosen to test their competitive binding for Bcl-2 protein using the ELISA (Table 2) , based on a previously described for assessing Bcl-2 binding affinity. [15] The pro-apoptotic Bcl2-inhibitory natural product gossypol, an agent under clinical investigation in cancer, [23] was used as a positive control in these experiments. Some of the tested compounds showed good-to-moderate antiproliferative activity with IC 50 values in the low micromolar range. Of those, compounds 1 and 8 had the most potent activity. Compound 1 was threefold more active than gossypol against the MDA-MB-231 cell line and 10-fold more active against the HeLa cell line. As the most active compound within this series, we were interested to know whether compound 1 possessed growth inhibitory activity against the normal breast epithelial cell line, MCF-10A (under the same test conditions as for the human cancer cell lines). Compound 1 was found to have an IC 50 value (MCF-10A) of 2.51 ± 0.29 μm, a slightly higher IC 50 value compared to that observed in the cancer cell lines and suggestive of selective anticancer activity. On the other hand, compound 8 showed similar activity to gossypol against both cancer cell lines.
However, none of the tested compounds had better competitive binding for Bcl-2 than gossypol ( Table 2 ). The indolebased oxadiazole thiols (compounds 1, 2 and 6, Figure 3 to Bcl-2 as shown in the ELISA assay. The ease of synthesis of these compounds and their relative low molecular weight made them attractive leads for further optimization toward development of a novel class of Bcl-2 inhibitors.
| Optimization and design of novel Bcl-2 inhibitors
The structure of the most active hit was modified in an attempt to further investigate the involvement of each part of the structure in the interaction with Bcl-2 with the aim of designing novel and easily accessible Bcl-2 inhibitors. The core structure of indolyl oxadiazoles represented by 1 was divided conceptually into four main regions as shown in Figure 4 .
In part A, the original 3-indolyl in our most active hit 1 was replaced by a naphthoxymethyl, phenoxymethyl, or indolylmethyl group to better understand the importance of the hydrophobic ring size in relation to interaction at the hydrophobic groove. For part B, the oxadiazole ring was replaced with the bioisosteric 1-aminotriazole to explore the importance of this ring in the activity of this series of compounds. Moreover, the opening of the ring was also explored (compound 17). Replacement of the ring with an open chain group was performed to study the extent of interaction of the 1,3,4-oxadiazole ring with Bcl-2 and try to obtain structurally simplified compounds. The distance between the 5-membered ring and the terminal phenyl group was varied to explore the best distance that placed these two rings in their optimum position inside the hydrophobic binding groove in Bcl-2; part C. Part D was modified by using different substitutions in the terminal phenyl group. In addition to the changes in the above four parts of the structure, the spatial arrangement of the groups around the 5-membered heterocyclic ring was also studied (compounds 18a-d). Vicinal substituted rings were designed to study the spatial positioning of the substituted groups around the central five-membered heterocycle. The chemical structures of newly designed compounds arising from consideration of structure-activity relationship around compound 1 are shown in Figure 5 . Table 3 summarizes the growth inhibitory effects of newly synthesized compounds 16a-o, 17, 18a-d, the previous hit compound 1 and gossypol as a reference compound against both breast MDA-MB-231 and cervical HeLa human cancer cell lines. Oxadiazolthio derivatives showed the best activity, where, replacement with triazolamine 16h, i showed complete loss of activity. The connector between the oxadiaxole and the phenyl also affected the potency and HeLa, respectively. As previously for compound 1, we studied the antiproliferative activity in a normal breast epithelial cell line, MCF-10A. The less potent IC 50 value of 3.16 ± 1.24 μm was indicative of selective anticancer activity within the cancer cell lines compared to normal control. Increasing the connection between the oxadiazole and the indole with a methylene group reduced the activity, as shown for compounds 16k and 16l. The type of the substituent on the phenyl ring also affected the potency, with the nitro group tending to have the best inhibitory activity. Replacement of the nitro group in 1 with an amino group in 16d abolished the growth inhibitory effect. However, more extended substituent at the 4-position improved the potency, where, 16f with an acetylamino group had an IC 50 of 16.45 μm on MDA-MB-231, while 16g with a phenoxyacetamido group was almost twofold more active than 16h with an IC 50 of 9.9 μm on MDA-MB-231. Variation in the type of 5-substituent of the 1,3,4-oxadiazole ring affected the potency. The 3-indolyl derivatives had the best activity. Replacement with naphthyloxylmethyl group in 16a showed some activity with IC 50 in low micromolar range in comparison with 37.97 μm in its 3-indolyl counterpart 3 in MDA-MB-231 cells (Table 1) . Opening of the fivemembered ring (compound 17) completely abolished the activity. Compounds 18a-d with vicinal substitution on the five-membered ring had some potency, but still much less active than the lead compound 1.
| BIOLOGICAL RESULTS

AND DISCUSSION
| In vitro antiproliferative activities
| Competitive binding to anti-apoptotic
Bcl-2 protein
To investigate whether the antiproliferative activity of the most active compound was derived from inhibition of the anti-apoptotic Bcl-2 protein, cellular active compounds 16g, 16j, and 18d were tested for their competitive binding for BCl-2 using ELISA. Table 4 summarizes the IC 50 values of these compounds in comparison with the lead compound 1.
The oxadiazole-5-amine 16j had the best affinity for Bcl-2 with an ELISA value of IC 50 of 4.27 μm, almost half the affinity of gossypol. The growth inhibitory effect of 16j coincides with its ability to bind to Bcl-2 as it had the most potent in vitro inhibitory effect on both HeLa and MDA-MB-231 cell lines. Indole-based oxadiazole thiols (1 and 16g) had moderate binding affinity to Bcl-2 with IC 50 around 16 μm. Compound 18d with vicinal substituted triazole also showed moderate affinity for Bcl-2 with an IC 50 of 10.66 μm.
| Molecular modeling
Molecular modeling studies were used to further our understanding of the structure-activity relationships of the compounds discussed above. The NMR structure of Bcl-2 co-crystallized with a ligand (PDB code: 1YSW) was used to define the active site. The BH3 binding groove on Bcl-2 is quite a large binding pocket can be viewed as composed of two large hydrophobic grooves (site 1 and site 2) and a shallow linker (aromatic ridge) (L) in between the two sites ( Figure 6 ).
All the synthesized compounds were subjected to a docking study to explore their affinity and binding mode to Bcl-2. The aim of the work was to rationalize the obtained biological data and explain the possible interactions that might take place between the novel compounds and anti-apoptotic Bcl-2 protein in comparison with crystallized ligand in order to optimize potent activity and selectivity. 
16.45 ± 2.5 32.70 ± 3.1
9.91 ± 0.54 8.6 ± 0.32 Values are mean ± SD of three experiments. Figure 7 shows the docking of 16j with 3-indoly (panels A and B) and 16m with 3-indolylmethyl counterpart (C and D). 16j with 3-indolyl substituent directly attached to the oxadiazole ring shows deep insertion of the 2-nitrophenyl group ring at site 2. The 3-indolyl group occupies the shallow linker site with optimized arene-cation interaction with Arg143. For 16m, the presence of the methylene connector between the 3-indolyl and the oxadiazole made different interaction mode with Bcl-2 with the 3-indolylmethyl group less deeply inserted at the hydrophobic site 1 and the substituted phenyl group at the shallow linker with no interaction with Arg143.
| Structure-activity relationship
Based on the cytotoxic profiles and Bcl-2 binding affinity of the designed compounds 16a-o, 17 and 18a-d, the following structural features were found to correlate with the activity.
Part A of the lead 1 (Figure 4 ) is that part which plays a role in the hydrophobic interaction at hydrophobic groves (site 2) of Bcl-2 mimicking Leu94 of Bim peptide. Bulky group showed better interaction. The docking showed deeper insertion into site 2 thus better hydrophobic interaction.
Part (B) is mostly located within the linker L, and it could play a role in the interaction with Bcl-2 by forming hydrogen bonding with Gly142 or Arg143 mimicking Asn102 or Asp99 in Bim. Both 1,3,4-oxadiazole and 4-amino-1,2,4-triazole were investigated, and only the oxadiazole ring showed activity. 4-Amino-1,2,4-triazole completely abolished the activity. Also, ring opening (compound 17) completely eliminated the activity.
Part (C) is located in the shallow linker L, and it plays a role in positioning part (D) in the hydrophobic groove site 1. For the active oxadiazole derivatives, 4-atom connectors optimize the position of part (D) into site 1 and give better inhibitory activity. Two-atom connectors have very weak inhibitory activity probably due to the inadequate insertion of part (D) into the hydrophobic groove site 1.
Part (D) is that part of the molecule that mostly occupies (site 1) in Bcl-2 mimicking Phe101 of the Bim peptide. Based on the biological results, both the site of substitution and its nature affect the activity. 4-Substituted phenyl generally gave the best results, where 4-NO 2 Ph was better than 2-NO 2 . Also, smaller substituents were less active, where the smaller F and NH 2 groups had less activity compared to larger electronwithdrawing groups like NO 2 . Moreover, extending the substitution at the para position of the phenyl ring could enhance the binding and gave better activity, where the more extended the substituent, the deeper its insertion into (site 1) making use of the hydrophobic interaction at this groove which in turn enhances the activity. 2-Methylphenoxyacetamide (16g) was more active than acetamide (16f), which in turn was better than NH 2 (16d). Both vicinal and 1,3-disubstituted rings showed activity as Bcl-2 inhibitors. However, vicinal arrangement of the groups needed more extended substitution to show activity, where the more extended the group, the more it is inserted into the hydrophobic groove (site 1) and the better is the activity. Also, the presence of more polar groups like hydroxyl (compound 18b) reduced the activity probably due to the less hydrophobic interaction at site 1. So, for vicinal substituted rings, the more extended and more hydrophobic the group, the better is the antiproliferative activity of the compound (18d compared to 18a).
| CONCLUSION
In summary, the design of novel non-peptidic molecules that act as Bcl-2 inhibitors began with virtual screening. The NMR structure of Bcl-2 co-crystallized with a peptide ligand was used for definition of the active site. A ligand-based 3D pharmacophore was created, and over 500,000 compounds were tested against the model followed by docking and visual inspection which eventually led to the discovery of 15 hits as potential Bcl-2 inhibitors. Biological evaluation of the chosen hits led to the discovery of 3,5-disubstituted 1,3,4-oxadiazole (compound 1) with moderate Bcl-2 inhibitory activity and a good cell inhibitory activity with IC 50 values in the submicromolar range. Compound 1 was modified at four different sites to investigate the structure-activity relationship of the 3,5-disubstituted 1,3,4-oxadiazoles with respect to the C3-substituent, the five-membered ring, the length of the connector at the C5, and the aromatic substitution at C5, in addition to the special arrangement of the groups around the five-membered core. The study led to the discovery of compound 16j with the best activity being almost 20-fold more active than gossypol in growth inhibitory assays in the cell lines tested and only twofold less active than gossypol as Bcl-2 inhibitor according to binding assays. Compound 16j represents a new class of small-molecule inhibitors targeting the anti-apoptotic Bcl-2 proteins. Further molecular modeling and molecular dynamic studies could give more insight into the molecular interactions between 16j and Bcl-2 which can lead to a design of more active compounds and translational progress. 
